Rockwell's Iron Therapy SFP Proves Its 'Metal' in Phase III
By Randy Osborne
Thursday, July 11, 2013
After taking a stock hit on the ominous promise of a conference call the next morning, Rockwell Medical Inc. turned investor worries around with news that the firm had encouraging top-line data to offer from the Phase III study known as CRUISE-1, testing SFP, an iron-delivery drug for chronic kidney disease patients on dialysis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.